SCHEMBL26100788

SCHEMBL26100788

Nc1cccc(C2OCCO2)c1Cl

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NSD2 O96028 1/20 0.40
CASP6 P55212 1/20 0.40
HTR2A P28223 1/20 0.35
HTR2C P28335 1/20 0.35
HTR2B P41595 1/20 0.35
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
ALDH1A1 P00352 2/20 0.32
NR4A2 P43354 1/20 0.32
TSHR P16473 2/20 0.32
TAAR1 Q96RJ0 1/20 0.31
GID4 Q8IVV7 1/20 0.30
SLC6A2 P23975 1/20 0.30
SLC6A4 P31645 1/20 0.30
SLC6A3 Q01959 1/20 0.30
CYP3A4 P08684 1/20 0.30
HPGD P15428 1/20 0.30
HSD17B10 Q99714 1/20 0.30
TDP1 Q9NUW8 1/20 0.30
P2RX7 Q99572 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26965532 0.80 NSD2 (0.41) NSD2CASP6ALDH1A1TSHRGID4
SCHEMBL29949338 0.80 NSD2 (0.41) NSD2CASP6ALDH1A1TSHRGID4
SCHEMBL5485539 0.79 NSD2 (0.40) NSD2CASP6HTR2ANPC1RAB9A
SCHEMBL3786896 0.74 OPRL1 (0.37) HTR2AHTR2CHTR2BALDH1A1NR4A2
SCHEMBL27783480 0.72 MMP2 (0.37) NSD2CASP6GID4TDP1P2RX7
SCHEMBL3727526 0.71 TSHR (0.36) HTR2AHTR2CHTR2BNPC1RAB9A
SCHEMBL3214155 0.71 KMT2A (0.49) HTR2AHTR2CHTR2BNPC1RAB9A
SCHEMBL3789205 0.71 CEL (0.38) HTR2AHTR2CHTR2BALDH1A1NR4A2
SCHEMBL3781868 0.71 CEL (0.42) ALDH1A1NR4A2TSHR
SCHEMBL30392759 0.70 TDP1 (0.41) HTR2AHTR2CHTR2BALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250051338-A1 TYK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2025-02-13 US disclosed
CN-119013277-A TYK2 degrading agent and application thereof 凯麦拉医疗公司 2024-11-22 CN disclosed
EP-4423086-A1 TYK2 DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2024-09-04 EP disclosed
WO-2023076161-A1 TYK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2023-05-04 WO disclosed
WO-2023076161-A1 TYK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2023-05-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250051338-A1 TYK2 DEGRADERS AND USES THEREOF TYK2, DYRK2, DYRK1A NSD2 1187/4885CASP6 4195/4885HTR2A 1931/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.